S-14
|
New perspectives in the pharmacological treatment of atrial fibrillation
|
|
|
Leopoldo Bianconi.
Division of Cardiology, San Filippo Neri Hospital, Rome, Italy
|
|
References
|
1.
|
BIANCONI L, BOCCADAMO R, PAPPALARDO A, GENTILI C, PISTOLESE M:
Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset.
Am J Cardiol 1989; 64: 335-338.
|
2.
|
MADRID AH, MORO C, MARIN HUETRA E, MESTRE JL, NOVO L, COSTA A:
Comparison of flecainide and procainamide in cardioversion of atrial fibrillation.
Eur Heart J 1993; 14: 1127-1131.
|
3.
|
ANDERSON J:
Acute treatment of atrial fibrillation and flutter.
J Am Coll Cardiol 1996; 17: 17-21.
|
4.
|
DONOVAN KD, POWER BM, HOCKINGS BE, DOBB GJ, LEE KY:
Intravenous flecainide versus amiodarone for recent onset atrial fibrillation.
Am J Cardiol 1995; 75: 693-697.
|
5.
|
COPLEN SE, ANTMAN EM, BERLIN JA, HEWITT P, CHALMERS TC:
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
Circulation 1990; 82: 1106-1116.
|
6.
|
WALDO AL, PRYSTOWSKY EN:
Drug treatment of atrial fibrillation in the managed care era.
Am J Cardiol 1998; 81: 23C-29C.
|
7.
|
PODRID PJ:
Amiodarone: reevaluation of an old drug.
Ann Int Med 1995; 122: 689-700.
|
8.
|
TASK FORCE OF THE WORKING GROUP ON ARRHYTHMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY:
The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms.
Eur Heart J 1991; 12: 1112-1131.
|
9.
|
STAMBLER BS, BECKMAN KJ, KADOSH AK, ET AL:
Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function.
Am J Cardiol 1997; 80: 458-463.
|
10.
|
LYNCH JL, BASKIN EP, NUTT EM, ET AL:
Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractorines for class III antiarrhythmic agents.
J Cardiovasc Pharmacol 1995; 25: 336-340.
|
11.
|
STAMBLER BS, WOOD MA, ELLENBOGEN KA, PERRY KT, WAKEFIELD LK, VANDERLUGT JT:
Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation.
Circulation 1996; 94: 1613-1621.
|
12.
|
ELLENBOGEN KA, STAMBLER BS, WOOD MA, ET AL:
Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a dose-response study.
J Am Coll Cardiol 1996; 28: 130-136.
|
13.
|
ABI-MANSOUR P, CARBERRY PA, MCCOWAN RJ, HENTHORN RW, DUNN GH, PERRY KT:
Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation.
Am Heart J 1998; 136: 632-642.
|
14.
|
VOLGMAN AS, CARBERRY PA, STAMBLER B, ET AL:
Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter of fibrillation.
J Am Coll Cardiol 1988; 31: 1414-1419.
|
15.
|
VOS MA, GOLITSIN SR, STANGL K, ET AL:
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation.
Heart 1998; 79: 568-575.
|
16.
|
KATRITSIS D, CAMM AJ:
New class III antiarrhythmic drugs.
Eur Heart J 1993; 14 (Suppl H): 93-99.
|
17.
|
SUTTORP MJ, POLLAK PE, VAN’T HOF A, RASMUSSEN HS, DUNSELMAN PH, KINGMA JH:
Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation and atrial flutter.
Am J Cardiol 1992; 69: 417-419.
|
18.
|
CRIJNS HJGM, VAN GELDER I, KINGMA JH, DUNSELMAN PHJM, GOSSELINK ATM, LIE KI:
Atrial flutter can be terminated by a class III antiarrhtyhmic drug but not by a class IC drug.
Eur Heart J 1994; 15: 1403-1408.
|
19.
|
SEDGWICK ML, LIP G, RAE AP, COBBE SM:
Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
Int J Cardiol 1995; 49: 159-166.
|
20.
|
FROST L, MORTENSEN PE, TINGLEFF J, PLATOU ES, CHRISTIANSEN EH, CHRISTIANSEN N:
Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after conronary bypass surgery.
Int J Cardiol 1997; 58: 135-140.
|
21.
|
FALK RH, POLLAK A, SINGH SN, GILMAN C:\WWW
Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter.
J Am Coll Cardiol 1997; 29: 385-390.
|
22.
|
BIANCONI L, DINELLI M, PAPPALARDO A, ET AL:
Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo-controlled study (abstract).
Circulation 1995; 92 (Suppl 1): 1-774.
|
23.
|
WALDO AL, CAMM AJ, DE RUYTER H, ET AL:
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction.
Lancet 1996; 348: 7-12.
|
24.
|
KOBER L:
A clinical trial on dofetilide in patients with acute myocardial infarction and left ventricular dysfunction: the DIAMOND Study (abstract).
Eur Heart J 1998; 19 (Suppl): 90.
|
25.
|
KOBER L:
Dofetilide, a new class III antiarrhythmic drug reduces hospital admissions for congestive heart failure – Secondary end points of the DIAMOND-CHF study (abstract).
J Am Coll Cardiol 1998; 31 (Suppl A): 33A.
|
26.
|
TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE, ET AL:
Dofetilide in patients with congestive heart failure and left ventricular dysfunction.
N Engl J Med 1999; 341: 857-865.
|
27.
|
GREENBAUM R, CAMPBELL TJ, CHANNER KS, ET AL:
Conversion of atrial fibrillation and maintainance of sinus rhythmy dofetilide. The EMERALD study (abstract).
Circulation 1998; 89 (Suppl I): I-633.
|
28.
|
WANG Z, FERMINI B, NATTEL S:
Sustained depolarization–induced outward current in human atrial myocites: evidence for a novel delayed rectifier K+ current in human ventricle.
Circ Res 1993; 73: 1061-1076.
|
29.
|
SATO R, HISATOME I, WASSERSTROM JA, ET AL:
Acetylcholine sensitive potassium channels in human atrial myocites.
Am J Physiol 1990; 259: H1730-H1735.
|
30.
|
SALATA JJ, BROOKS RR:
Pharmacology of azimilide dihydrocloride (NE10064), a class III antiarrhythmic agent.
Cardiovasc Drug Rev 1997; 15: 137-156.
|
31.
|
NATTEL F, LIU L, ST-GEORGE D:
Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties: concentration dependance and comparison with the IKr blocker dofetilide.
Cardiovasc Res 1998; 37: 627-635.
|
32.
|
Black SC, Butterfield JL, Lucchesi RB:
Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
J Cardiovasc Pharmacol 1993; 22: 810-818.
|
33.
|
DREXLER AP, AL-KHALDI H, MAYNARD AE, ET AL:
Comparison of azimilide dihidrochloride (NE-10064) and selected class III antiarrhythmic agents in a rabbit model of proarrhythmia (abstract).
FASEB J 1996; 10: A33.
|
34.
|
KARAM R, MARCELLO S, BROOKS RR, COREY AE, MOORE A:
Azimilide dihydrocloride, a novel antiarrhythmic agent.
Am J Cardio 1998; 81: 40D-46D.
|
35.
|
WALLACE AA, STUPIENSKI RF, BASKIN EP, ET AL:
Cardiac electrophysiologic antiarrhythmic actions of tedisamil.
J Pharmacol Exp Ter 1995; 273: 168-175.
|
36.
|
THORMANN J, MITROVIC V, RIEDEL H, ET AL:
Tedisamil (KC8857) is a new specific bradycardic drug. Does it also influence myocardial contractility? Analysis by the conductance technique in coronary artery disease.
Am Heart J 1993; 125: 1233-1245.
|
37.
|
CAMM AJ, YAP YG:
What should we expect from the next generation of antiarrhythmic drugs?
J Cardiovasc Electrophysiol 1999; 19: 307-317.
|
38.
|
LEE JH, ROSENSHTRAUKT L, BELOSCAPKO G, ET AL:
The electrophysiologic effects of ersentilide on canine hearts.
Eur J Pharmacol 1995; 285: 25-35.
|
